Oxford Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Oxford Asset Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-27,042	Closed	-$152K	–	983
2016 Q1	$152K	Sell	27,042 -38,433	-59%	-$499K	﹤0.01%	729
2015 Q4	$1.14M	Buy	65,475 +12,763	+24%	+$304K	0.03%	506
2015 Q3	$1.11M	Buy	+52,712	New	+$1.81M	0.04%	387
2014 Q3	–	Sell	-13,441	Closed	-$833K	–	875
2014 Q2	$833K	Sell	13,441 -42,374	-76%	-$2.46M	0.03%	515
2014 Q1	$3.63M	Buy	+55,815	New	+$3.78M	0.11%	267

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Oxford Asset Management's OREX Position: Q2 2016 in Review

Oxford Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 27,042 shares — an estimated $152K sold.

Oxford Asset Management first reported a position in OREX in Q1 2014 and held it in 5 quarters. The position peaked at $3.63M in Q1 2014. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Oxford Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Oxford Asset Management sold 27,042 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $152K.
Oxford Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q1 2014 and held it in 5 quarters.
Oxford Asset Management's Orexigen Therapeutics, Inc. position peaked at $3.63M in Q1 2014.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Oxford Asset Management's 13F filing for Q2 2016, filed 8 Aug 2016.